

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Ebata 1



Section 1. Identifying Inform	nation	
Given Name (First Name) Shigeto	2. Surname (Last Name) Ebata	3. Date 03-February-2016
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Hirotaka Haro
	nbar Degenerative Disord	cement After Posterior or Transforaminal Lumbar Interbody ers: A Multicenter, Prospective, Randomized Study
Section 2. The Work Under C	onsideration for Publi	cation
		n a third party (government, commercial, private foundation, etc.) for ata monitoring board, study design, manuscript preparation,
Are there any relevant conflicts of interest		
If yes, please fill out the appropriate info Excess rows can be removed by pressin		ve more than one entity press the "ADD" button to add a row.
Name of Institution/Company	Grant? Personal No	n-Financial Other? Comments
Asahi Kasei Pharma Corporation	✓	
Section 3. Relevant financial	activities outside the	submitted work.
of compensation) with entities as descr	ibed in the instructions. U port relationships that we	nether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by tree present during the 36 months prior to publication.
Section 4. Intellectual Proper	rty Patents & Copyri	ghts
Do you have any patents, whether plan	ned, pending or issued, bi ormation below. If you hav	

Ebata 2



Patent [?]	Pending?	Issued?	Licensed ?	Royalties?	Licensee?	Comments	
JP2014-181229	✓						
Section 5. Relationshi	ps not cov	ered abo	ove				
Are there other relationships or potentially influencing, what yo				eive to have	influenced, or tha	at give the appearance of	
Yes, the following relationsh	nips/conditio	ns/circun	nstances are	e present (ex	plain below):		
✓ No other relationships/cond	litions/circur	nstances	that presen	t a potential	conflict of interes	st	
At the time of manuscript accep On occasion, journals may ask a							nents.
Section 6. Disclosure S	Statement						
Based on the above disclosures, below.	, this form w	ill automa	atically gene	erate a disclo	sure statement, v	which will appear in the box	
Dr. Ebata reports grants from A patent JP2014-181229 pending		narma Coi	rporation, c	during the co	nduct of the stud	ly; In addition, Dr. Ebata has	5 a

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Ebata 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Haro 1



Section 1. Identifying Inform		
Identifying Inform	nation	
Given Name (First Name) Hirotaka	2. Surname (Last Name) Haro	3. Date 13-January-2016
4. Are you the corresponding author?	✓ Yes No	
	mbar Degenerative Disorders: A	nt After Posterior or Transforaminal Lumbar Interbody Multicenter, Prospective, Randomized Study
Section 2. The Work Under C	onsideration for Publication	n
		d party (government, commercial, private foundation, etc.) for initoring board, study design, manuscript preparation,
Are there any relevant conflicts of inter	est? ✓ Yes No	
		re than one entity press the "ADD" button to add a row.
Excess rows can be removed by pressir		
Name of Institution/Company	Grant Personal Non-Fina Fees Suppo	Other• Comments
Asahi Kasei Pharma Corporation	√	
Section 3. Relevant financial	activities outside the subm	itted work.
of compensation) with entities as descri	ibed in the instructions. Use one port relationships that were pre	you have financial relationships (regardless of amount e line for each entity; add as many lines as you need by esent during the 36 months prior to publication.
Section 4		
Section 4. Intellectual Prope	rty Patents & Copyrights	
Do you have any patents, whether plar If yes, please fill out the appropriate inf Excess rows can be removed by pressir	ormation below. If you have mo	relevant to the work? Yes No No re than one entity press the "ADD" button to add a row.

Haro 2



Patent?	Pending?	Issued?	Licensed ?	Royalties?	Licensee?	Comments	
IP2014-181229	✓						
Section 5. Relationshi	ps not cov	ered ab	ove				
Are there other relationships or potentially influencing, what yo			•	eive to have	influenced, or tha	at give the appearance of	
Yes, the following relationsh	ips/conditio	ns/circun	nstances are	e present (ex	plain below):		
✓ No other relationships/cond	itions/circur	nstances	that presen	t a potential	conflict of interes	st	
On occasion, journals may ask a	At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.						
Section 6. Disclosure S	tatement						
Based on the above disclosures, below.	this form wi	ill automa	atically gene	erate a disclo	sure statement, v	which will appear in the box	
Dr. Haro reports grants from Ass patent JP2014-181229 pending		arma Cor	poration, d	uring the coi	nduct of the study	r; In addition, Dr. Haro has a	à

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Haro 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not **Royalties:** Funds are coming in to you or your institution due to your

patent

Hasegawa 1



Section 1. Identifying Inform	•	
Identifying Inform	nation	
1. Given Name (First Name) Tomohiko	2. Surname (Last Name) Hasegawa	3. Date 03-February-2016
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Hirotaka Haro
	nbar Degenerative Disorde	cement After Posterior or Transforaminal Lumbar Interbody ers: A Multicenter, Prospective, Randomized Study
Section 2. The Work Under Co	onsideration for Public	cation
		a third party (government, commercial, private foundation, etc.) for ta monitoring board, study design, manuscript preparation,
Are there any relevant conflicts of interest	est? ✓ Yes No	
If yes, please fill out the appropriate info Excess rows can be removed by pressin	-	re more than one entity press the "ADD" button to add a row.
Name of Institution/Company	Grant? Personal Nor	n-Financial upport? Comments
Asahi Kasei Pharma Corporation	✓	
Section 3. Relevant financial	activities outside the s	ubmitted work.
of compensation) with entities as descr	ibed in the instructions. Us port relationships that wer	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by the present during the 36 months prior to publication.
Section 4. Intellectual Brono	rty Patents & Copyri <u>c</u>	vlate.
mtellectual Propel	rty Patents & Copyrig	ints —
Do you have any patents, whether plan If yes, please fill out the appropriate info Excess rows can be removed by pressin	ormation below. If you hav	oadly relevant to the work? Yes No ee more than one entity press the "ADD" button to add a row.

Hasegawa 2



Patent?	Pending?	Issued?	Licensed	Royalties?	Licensee?	Comments	
JP2014-181229	✓						
Section 5. Relationshi	ps not cov	ered abo	ove				
Are there other relationships or potentially influencing, what yo				eive to have	influenced, or tha	at give the appearance of	
Yes, the following relationsh	ips/conditio	ns/circun	nstances are	e present (ex	plain below):		
✓ No other relationships/cond	itions/circur	nstances	that presen	t a potential	conflict of interes	st	
At the time of manuscript accep On occasion, journals may ask a							nents.
Section 6. Disclosure S	tatement						
Based on the above disclosures, below.	this form wi	ill automa	atically gene	erate a disclo	sure statement, v	which will appear in the box	
Dr. Hasegawa reports grants fro Hasegawa has a patent JP2014-			a Corporati	on, during tl	ne conduct of the	study; In addition, Dr.	

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Hasegawa 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Isogai 1



Section 1. Identifying Inform	ation						
Given Name (First Name) Yukihiro	2. Surname (Last Name) Isogai		3. Date 08-February-2016				
4. Are you the corresponding author?	Yes ✓ No	Corresponding Autho	or's Name				
5. Manuscript Title Role of Weekly Teriparatide Administration in Bony Union Enhancement After Posterior or Transforaminal Lumbar Interbod Fusion for Osteoporosis-associated Lumbar Degenerative Disorders: A Multicenter, Prospective, Randomized Study 6. Manuscript Identifying Number (if you know it)							
Section 2. The Work Under Co	onsideration for Public	nation.					
Did you or your institution at any time rece any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	ive payment or services from but not limited to grants, daest? Yes No Normation below. If you hav	a third party (governme ta monitoring board, st	ent, commercial, private foundation, etc.) for udy design, manuscript preparation, ty press the "ADD" button to add a row.				
Name of Institution/Company	Grant'	n-Financial Other?	Comments				
Asahi Kasei Pharma Corporation	✓		l am employee of Asahi Kasei Pharma Corporation				
Section 3. Relevant financial	activities outside the s	ubmitted work.					
Place a check in the appropriate boxes i of compensation) with entities as descri clicking the "Add +" box. You should rep Are there any relevant conflicts of interes	bed in the instructions. Us port relationships that wer	e one line for each er	ntity; add as many lines as you need by				
Section 4. Intellectual Proper	tu. Datauta 9 Caussia	.hea					
Intellectual Proper	ty Patents & Copyrig	ints					
Do you have any patents, whether plan If yes, please fill out the appropriate info Excess rows can be removed by pressing	ormation below. If you hav	•	work? Yes No ty press the "ADD" button to add a row.				

Isogai 2



Patent?	Pending?	Issued?	Licensed ?	Royalties?	Licensee?	Comments	
IP2014-181229	✓						
Section 5. Relationshi	ps not cov	ered abo	ove				
Are there other relationships or potentially influencing, what yo			•	eive to have	influenced, or tha	at give the appearance of	
Yes, the following relationsh	ips/conditio	ns/circun	nstances are	e present (ex	plain below):		
✓ No other relationships/cond	itions/circur	nstances	that presen	t a potential	conflict of interes	st	
On occasion, journals may ask a	At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.						
Section 6. Disclosure S	tatement						
Based on the above disclosures, below.	this form wi	ill automa	atically gene	erate a disclo	sure statement, v	vhich will appear in the box	
Dr. Isogai reports grants and otl Isogai has a patent JP2014-1812			Pharma Cor _l	poration, du	ring the conduct	of the study; In addition, D	r.
isoyai nas a patent JP2014-1812	229 penaing						

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Isogai 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Matsuyama 1



Section 1. Identifying Inform		
Identifying Inform	nation	
Given Name (First Name) Yukihiro	2. Surname (Last Name) Matsuyama	3. Date 03-February-2016
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Hirotaka Haro
	nbar Degenerative Disorde	ement After Posterior or Transforaminal Lumbar Interbody ers: A Multicenter, Prospective, Randomized Study
Section 2. The Work Under Co	onsideration for Public	cation
		a third party (government, commercial, private foundation, etc.) for ta monitoring board, study design, manuscript preparation,
Are there any relevant conflicts of interest	est? ✓ Yes No	
If yes, please fill out the appropriate info Excess rows can be removed by pressin	-	re more than one entity press the "ADD" button to add a row.
Name of Institution/Company	Grant? Personal Nor	n-Financial upport? Comments
Asahi Kasei Pharma Corporation	✓	
Section 3. Relevant financial	activities outside the s	ubmitted work.
of compensation) with entities as descr	ibed in the instructions. Us port relationships that wer	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by se present during the 36 months prior to publication.
Section 4. Intellectual Proper	rty Patents & Copyri <u>c</u>	uhts
intellectuari iopei	rty - Tatems & copyrig	
Do you have any patents, whether plan If yes, please fill out the appropriate info Excess rows can be removed by pressin	ormation below. If you hav	oadly relevant to the work? Yes No ee more than one entity press the "ADD" button to add a row.

Matsuyama 2



Patent?	Pending?	Issued?	Licensed?	Royalties?	Licensee?	Comments	
JP2014-181229	✓						
Section 5. Relationshi	ps not cov	ered abo	ove				
Are there other relationships or potentially influencing, what yo				eive to have	influenced, or tha	at give the appearance of	
Yes, the following relationsh	ips/conditio	ns/circun	nstances are	e present (ex	plain below):		
✓ No other relationships/cond	itions/circur	nstances	that presen	t a potential	conflict of interes	t	
At the time of manuscript accep On occasion, journals may ask a							nents.
Section 6. Disclosure S	tatement						
Based on the above disclosures, below.	this form wi	ill automa	atically gene	erate a disclo	sure statement, v	which will appear in the box	
Dr. Matsuyama reports grants fi Matsuyama has a patent JP2014			ma Corporat	tion, during	the conduct of th	e study; In addition, Dr.	

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Matsuyama 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Mukaiyama 1



C. distant		
Section 1. Identifying Inform	nation	
Given Name (First Name) Keijiro	2. Surname (Last Name) Mukaiyama	3. Date 03-February-2016
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Hirotaka Haro
·	nbar Degenerative Disord	cement After Posterior or Transforaminal Lumbar Interbody ers: A Multicenter, Prospective, Randomized Study
Section 2. The Work Under C	onsideration for Public	cation
any aspect of the submitted work (including statistical analysis, etc.)?	g but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ata monitoring board, study design, manuscript preparation,
Are there any relevant conflicts of intere		
If yes, please fill out the appropriate info Excess rows can be removed by pressin		ve more than one entity press the "ADD" button to add a row.
Name of Institution/Company	Grant? Personal No	on-Financial Other? Comments
Asahi Kasei Pharma Corporation	✓	
Section 2		
Section 3. Relevant financial	activities outside the	submitted work.
of compensation) with entities as descr	ibed in the instructions. Us port relationships that we	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication.
Section 4. Intellectual Proper	rty Patents & Copyric	ghts
Do you have any patents, whether plan	ned, pending or issued, br ormation below. If you hav	

Mukaiyama 2



Patent?	Pending?	Issued?	Licensed?	Royalties?	Licensee?	Comments	
JP2014-181229	√						
Section 5. Relationshi	ps not cov	ered abo	ove				
Are there other relationships or potentially influencing, what yo				eive to have	influenced, or tha	at give the appearance of	
Yes, the following relationsh	ips/conditio	ns/circun	nstances are	e present (ex	plain below):		
✓ No other relationships/cond	itions/circur	nstances	that presen	t a potential	conflict of interes	t	
At the time of manuscript accep On occasion, journals may ask a	-						nents.
Section 6. Disclosure S	tatement						
Based on the above disclosures, below.	this form wi	ll automa	atically gene	erate a disclo	sure statement, v	which will appear in the box	
Dr. Mukaiyama reports grants fi Mukaiyama has a patent JP2014			ma Corpora 1	tion, during	the conduct of th	e study; In addition, Dr.	

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Mukaiyama 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Ohba 1



Section 1.	Identifying Inform	ation					
1. Given Name (Fir Tetsuro	, ,	2. Surname (La Ohba	ast Name)			3. Date 02-Februa	ry-2016
4. Are you the corr	esponding author?	Yes ✓	_	Correspond Hirotaka H	ling Author's aro	Name	
Fusion for Osteop	eriparatide Administrat oorosis-associated Lum	nbar Degenerat					
6. Manuscript Iden	itifying Number (if you kn	ow it)					
Section 2.	The Work Under Co	onsideration	for Publicat	tion			
any aspect of the su statistical analysis, e	titution at any time recei ubmitted work (including	ve payment or so but not limited t	ervices from a t	hird party (
If yes, please fill o	out the appropriate info	ormation below	r. If you have r	nore than	one entity	oress the "ADD	" button to add a row.
Name of Instituti	on/Company	Grant		inancial	Other?	Comments	
Asahi Kasei Pharma Co	orporation	V					
Section 3.	Relevant financial	activities out	side the suk	omitted v	work.		
of compensation) clicking the "Add	he appropriate boxes i) with entities as descri +" box. You should rep	bed in the instr port relationshi	ructions. Use on that were r	one line fo	r each entit	y; add as many	lines as you need by
Are there any rele	evant conflicts of intere	est? Yes	√ No				
Section 4.	Intellectual Proper	ty Patents	& Copyright	ts			
Do you have any	patents, whether plani	ned, pending o	r issued, broa	dly relevar	nt to the wo	ork? Yes	✓ No

Ohba 2



Section 5. Relationships not severed above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Ohba reports grants from Asahi Kasei Pharma Corporation, during the conduct of the study; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Ohba 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Ojima 1



Section 1. Identifying Inform	nation			
1. Given Name (First Name) Toshiyuki	2. Surname (Last Name) Ojima		3. Date 02-February-2016	
4. Are you the corresponding author?		Corresponding Author's Name Hirotaka Haro		
5. Manuscript TitleRole of Weekly Teriparatide AdministraFusion for Osteoporosis-associated Lun6. Manuscript Identifying Number (if you kr	nbar Degenerative Disorders:		•	
Section 2. The Work Under Co	onsideration for Publicat	ion		
Did you or your institution at any time rece any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	but not limited to grants, data r			
If yes, please fill out the appropriate info Excess rows can be removed by pressin		nore than one entity pr	ress the "ADD" button to add a row.	
Name of Institution/Company	Grant	inancial Other? Co	omments	
Asahi Kasei Pharma Corporation	V			
Section 3. Relevant financial	activities outside the sub	mitted work.		
Place a check in the appropriate boxes in the appropriate boxes in the compensation) with entities as describle clicking the "Add +" box. You should repart there any relevant conflicts of interest.	ibed in the instructions. Use c port relationships that were p	one line for each entity;	; add as many lines as you need by	
Section 4. Intellectual Proper	rty Patents & Copyright	s		
Do you have any patents, whether plan	ned, pending or issued, broad	dly relevant to the worl	k? ☐ Yes 🗸 No	

Ojima 2



Section 5. Relationships not covered above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Ojima reports grants from Asahi Kasei Pharma Corporation, during the conduct of the study; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Ojima 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Shibata 1



Section 1. Identifying Inform	nation			
1. Given Name (First Name) Yosuke	2. Surname (Last Name) Shibata		3. Date 08-February-2016	
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Hirotaka Haro		
5. Manuscript TitleRole of Weekly Teriparatide AdministrateFusion for Osteoporosis-associated Lum6. Manuscript Identifying Number (if you known)	nbar Degenerative Disorde			
Section 2. The Work Under Co	onsideration for Public	cation		
Did you or your institution at any time recei any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	but not limited to grants, da			
If yes, please fill out the appropriate info		e more than one enti	ty press the "ADD" button to add a row.	
Name of Institution/Company	Grant	n-Financial Other?	Comments	
Asahi Kasei Pharma Corporation	✓			
Section 3. Relevant financial	activities outside the s	submitted work.		
Place a check in the appropriate boxes i of compensation) with entities as descri clicking the "Add +" box. You should rep Are there any relevant conflicts of intere	bed in the instructions. Us port relationships that wer	se one line for each en	itity; add as many lines as you need by	
Section 4. Intellectual Proper	ty Patents & Copyric	ghts		
Do you have any patents, whether plant	ned, pending or issued, br	oadly relevant to the	work? Yes V	

Shibata 2



Section 5. Polationships not severed above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Shibata reports grants from Asahi Kasei Pharma Corporation, during the conduct of the study; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Shibata 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Takahashi 1



Costion 1		
Section 1. Identifying Inform	nation	
1. Given Name (First Name) Jun	2. Surname (Last Name) Takahashi	3. Date 02-February-2016
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Hirotaka Haro
·	nbar Degenerative Disorde	cement After Posterior or Transforaminal Lumbar Interbody ers: A Multicenter, Prospective, Randomized Study
Section 2. The Work Under Co	onsideration for Public	cation
any aspect of the submitted work (including statistical analysis, etc.)?	but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ata monitoring board, study design, manuscript preparation,
Are there any relevant conflicts of intere		
If yes, please fill out the appropriate info Excess rows can be removed by pressin	•	ve more than one entity press the "ADD" button to add a row.
Name of Institution/Company	Grant? Personal No	on-Financial Other? Comments
Asahi Kasei Pharma Corporation	✓	
Continue 2		
Section 3. Relevant financial	activities outside the	submitted work.
of compensation) with entities as descr	bed in the instructions. Us port relationships that wer	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication .
Section 4. Intellectual Proper	rty Patents & Copyric	ghts
Do you have any patents, whether plan	ned, pending or issued, br ormation below. If you hav	

Takahashi 2



Patent?	Pending?	Issued?	Licensed?	Royalties?	Licensee?	Comments	
JP2014-181229	√						
Section 5. Relationshi	ps not cov	ered abo	ove				
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?							
Yes, the following relationsh	nips/conditio	ns/circun	nstances are	e present (ex	plain below):		
✓ No other relationships/conditions/circumstances that present a potential conflict of interest							
At the time of manuscript accep On occasion, journals may ask a	-						nents.
Section 6. Disclosure S	tatement						
Based on the above disclosures, below.	this form wi	ill automa	atically gene	erate a disclo	sure statement, v	which will appear in the box	
Dr. Takahashi reports grants fro Takahashi has a patent JP2014-			a Corporatio	on, during th	ne conduct of the	study; In addition, Dr.	

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Takahashi 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Yamagata 1



Section 1. Identifying Inform	nation			
Given Name (First Name) Zentaro	2. Surname (Last Name) Yamagata		3. Date 08-February-2016	
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Hirotaka Haro		
5. Manuscript TitleRole of Weekly Teriparatide AdministrationFusion for Osteoporosis-associated Lun6. Manuscript Identifying Number (if you known to be a support of the control of t	nbar Degenerative Disorde		•	
Section 2. The Work Under Co	onsideration for Public	cation		
Did you or your institution at any time rece any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	but not limited to grants, da			
If yes, please fill out the appropriate info Excess rows can be removed by pressing		e more than one entit	ry press the "ADD" button to add a row.	
Name of Institution/Company	Grant? Personal Nor	n-Financial Other?	Comments	
Asahi Kasei Pharma Corporation	✓			
Section 3. Relevant financial	activities outside the s	ubmitted work.		
Place a check in the appropriate boxes i of compensation) with entities as descri clicking the "Add +" box. You should rep Are there any relevant conflicts of intere	ibed in the instructions. Us port relationships that wer	se one line for each en	tity; add as many lines as you need by	
Section 4. Intellectual Proper	rty Patents & Copyrig	yhts		
Do you have any patents, whether plan	ned, pending or issued, br	oadly relevant to the v	work? Yes V No	

Yamagata 2



Section 5. Polationships not severed above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Yamagata reports grants from Asahi Kasei Pharma Corporation, during the conduct of the study; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Yamagata 3